490
Participants
Start Date
March 5, 2024
Primary Completion Date
March 31, 2027
Study Completion Date
March 31, 2027
LY4101174
Intravenous
RECRUITING
Institut Jules Bordet, Anderlecht
RECRUITING
Austin Health, Heidelberg
RECRUITING
Icon Cancer Centre Kurralta Park, Kurralta Park
RECRUITING
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
NOT_YET_RECRUITING
Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola
RECRUITING
Institut Paoli-Calmettes, Marseille
RECRUITING
MD Anderson Cancer Center, Madrid
RECRUITING
Hospital Universitario 12 de Octubre, Madrid
RECRUITING
Emory University, Atlanta
RECRUITING
AdventHealth Orlando, Orlando
RECRUITING
Hospital Universitario Virgen Del Rocio, Seville
RECRUITING
Centre Oscar Lambret, Lille
RECRUITING
Washington University School of Medicine, St Louis
RECRUITING
Institut de cancérologie Strasbourg Europe, Strasbourg
RECRUITING
Centre Leon Berard, Lyon
RECRUITING
Gustave Roussy, Villejuif
NOT_YET_RECRUITING
Peking University First Hospital, Beijing
NOT_YET_RECRUITING
Shanghai East Hospital, Shanghai
NOT_YET_RECRUITING
Hunan Cancer Hospital, Changsha
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
UT Southwestern Medical Center, Dallas
RECRUITING
South Texas Accelerated Research Therapeutics (START), San Antonio
RECRUITING
National Cancer Center Hospital, Chūōku
RECRUITING
National Cancer Center Hospital East, Kashiwa
RECRUITING
The Cancer Institute Hospital of JFCR, Kōtō City
RECRUITING
Kyoto University Hospital, Kyoto
RECRUITING
Hospital Universitari Vall d'Hebron, Barcelona
Eli Lilly and Company
INDUSTRY